Presentation TCT 2020

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Presenter: Jeffrey W. Moses

October 15, 2020

REGISTER for free or LOG IN to view this content

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Structural Heart

Aortic Valve

Presentation

TCT 2020

REFLECT II

Jeffrey Moses

Up Next

Presentation TCT 2020

Closure of Iatrogenic Atrial Septal Defects Following Transcatheter Mitral Valve Repair – The Randomized MITHRAS Trial

Presenter: Philipp Lurz

October 15, 2020

More slides +

Presentation TCT 2020

Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease: The Disrupt CAD III Study

Presenter: Dean J. Kereiakes

October 15, 2020

Presentation TCT 2020

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

Presenter: Roxana Mehran

October 15, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.